Piper Jaffray Cos. assumed coverage on shares of CRISPR Therapeutics AG Common Shares (NASDAQ:CRSP) in a report issued on Monday. The firm set an “overweight” rating and a $21.00 price target on the stock. Piper Jaffray Cos.’s price objective indicates a potential upside of 15.70% from the stock’s current price.

Separately, Barclays PLC assumed coverage on shares of CRISPR Therapeutics AG Common Shares in a research note on Monday. They set an “overweight” rating and a $22.00 target price for the company.

CRISPR Therapeutics AG Common Shares (NASDAQ:CRSP) opened at 18.15 on Monday. CRISPR Therapeutics AG Common Shares has a 1-year low of $13.75 and a 1-year high of $18.88. The stock’s market cap is $95.51 million. The firm’s 50 day moving average price is $15.86 and its 200-day moving average price is $15.86.

In related news, major shareholder Corp /De/ Celgene acquired 800,150 shares of the firm’s stock in a transaction on Monday, October 24th. The stock was bought at an average price of $14.00 per share, for a total transaction of $11,202,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Simeon George acquired 66,500 shares of the firm’s stock in a transaction on Monday, October 24th. The stock was bought at an average price of $14.00 per share, with a total value of $931,000.00. The disclosure for this purchase can be found here.

5 Day Chart for NASDAQ:CRSP

Receive News & Stock Ratings for CRISPR Therapeutics AG Common Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics AG Common Shares and related stocks with our FREE daily email newsletter.